{"id":18159,"date":"2023-06-02T22:26:00","date_gmt":"2023-06-02T14:26:00","guid":{"rendered":"https:\/\/flcube.com\/?p=18159"},"modified":"2024-12-15T22:29:48","modified_gmt":"2024-12-15T14:29:48","slug":"sirnaomics-initiates-phase-i-clinical-trial-for-anticoagulant-drug-candidate-stp122g","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=18159","title":{"rendered":"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G"},"content":{"rendered":"\n

Sirnaomics Ltd (HKG: 2257<\/a>) has announced the first systemic dosing of a Phase I clinical trial for its leading RNAi drug candidate, STP122G, an anticoagulation treatment. STP122G, developed using Sirnaomics’ GalNAc RNAi delivery platform technology GalAhead, targets Factor XI and has broad applicability across various disease indications, including the potential prevention and treatment of stroke after atrial fibrillation, support for cancer patients post-immunotherapy, and enhancement of recovery following total knee replacement.<\/p>\n\n\n\n

Design and Objectives of the Phase I Study<\/strong>
The Phase I study is a single-center, randomized, double-blind, and sequential cohort trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single ascending dose of STP122G when administered subcutaneously to healthy participants. The trial will compare the safety and tolerability among five different doses of STP122G (25 mg, 50 mg, 100 mg, 200 mg, 400 mg) to select the most appropriate dose for future studies. The study plans to recruit a total of 40 participants.<\/p>\n\n\n\n

Significance of the Trial and Future Prospects<\/strong>
This trial marks a significant step in the development of STP122G, which has the potential to revolutionize anticoagulant therapy. The data generated from this study will be crucial in determining the safety profile and optimal dosing strategy for STP122G, paving the way for further clinical development and potentially transforming the treatment landscape for various conditions requiring anticoagulant intervention.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,64,440],"class_list":["post-18159","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-rnai-aso","tag-sirnaomics"],"yoast_head":"\nSirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical trial for its leading RNAi drug candidate, STP122G, an anticoagulation treatment. STP122G, developed using Sirnaomics' GalNAc RNAi delivery platform technology GalAhead, targets Factor XI and has broad applicability across various disease indications, including the potential prevention and treatment of stroke after atrial fibrillation, support for cancer patients post-immunotherapy, and enhancement of recovery following total knee replacement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=18159\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=18159\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-02T14:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-15T14:29:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18159#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18159\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G\",\"datePublished\":\"2023-06-02T14:26:00+00:00\",\"dateModified\":\"2024-12-15T14:29:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18159\"},\"wordCount\":237,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"RNAi \\\/ ASO\",\"Sirnaomics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18159#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18159\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=18159\",\"name\":\"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-06-02T14:26:00+00:00\",\"dateModified\":\"2024-12-15T14:29:48+00:00\",\"description\":\"Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical trial for its leading RNAi drug candidate, STP122G, an anticoagulation treatment. STP122G, developed using Sirnaomics' GalNAc RNAi delivery platform technology GalAhead, targets Factor XI and has broad applicability across various disease indications, including the potential prevention and treatment of stroke after atrial fibrillation, support for cancer patients post-immunotherapy, and enhancement of recovery following total knee replacement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18159#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18159\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18159#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G - Insight, China's Pharmaceutical Industry","description":"Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical trial for its leading RNAi drug candidate, STP122G, an anticoagulation treatment. STP122G, developed using Sirnaomics' GalNAc RNAi delivery platform technology GalAhead, targets Factor XI and has broad applicability across various disease indications, including the potential prevention and treatment of stroke after atrial fibrillation, support for cancer patients post-immunotherapy, and enhancement of recovery following total knee replacement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=18159","og_locale":"en_US","og_type":"article","og_title":"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=18159","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-06-02T14:26:00+00:00","article_modified_time":"2024-12-15T14:29:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=18159#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=18159"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G","datePublished":"2023-06-02T14:26:00+00:00","dateModified":"2024-12-15T14:29:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=18159"},"wordCount":237,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","RNAi \/ ASO","Sirnaomics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=18159#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=18159","url":"https:\/\/flcube.com\/?p=18159","name":"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-06-02T14:26:00+00:00","dateModified":"2024-12-15T14:29:48+00:00","description":"Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical trial for its leading RNAi drug candidate, STP122G, an anticoagulation treatment. STP122G, developed using Sirnaomics' GalNAc RNAi delivery platform technology GalAhead, targets Factor XI and has broad applicability across various disease indications, including the potential prevention and treatment of stroke after atrial fibrillation, support for cancer patients post-immunotherapy, and enhancement of recovery following total knee replacement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=18159#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=18159"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=18159#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18159"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18159\/revisions"}],"predecessor-version":[{"id":18161,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18159\/revisions\/18161"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}